Arcellx, Inc.
ACLX
Kedudukan dalam Saham
#2776
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Harga Saham
$115.07
Disegerakkan terakhir: 2026-05-15
Modal Pasaran
$6.73B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
32.61%
Negara
US
Perdagangan Arcellx, Inc. (ACLX)
Kategori
Healthcare
Pendapatan untuk Arcellx, Inc. (ACLX)
Pendapatan pada Dec 2025 TTM: $-228.87M
Menurut laporan kewangan terkini Arcellx, Inc., pendapatan semasa syarikat ialah $-228.87M. Pada tahun 2023, syarikat memperoleh pendapatan sebanyak $-70.03M, peningkatan berbanding pendapatan pada tahun 2022 yang berjumlah $-188.68M. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Arcellx, Inc. dari 2018 hingga 2026
Pendapatan pada akhir setiap tahun
| Tahun | Pendapatan | Ubah |
|---|---|---|
| 2026 (TTM) | $-228.87M | 117.39% |
| 2024 | $-105.28M | 50.34% |
| 2023 | $-70.03M | -62.89% |
| 2022 | $-188.68M | 190.41% |
| 2021 | $-64.97M | 102.43% |
| 2020 | $-32.10M | 78.58% |
| 2019 | $-17.97M | 116.32% |
| 2018 | $-8.31M | 0.00% |
Pendapatan untuk syarikat atau pesaing serupa
| Syarikat | Pendapatan | Perbezaan Pendapatan | Negara |
|---|---|---|---|
| $5.27B | -2,404.81% |
US
|
|
| $-3.09B | 1,248.83% |
US
|
|
| $-4.02B | 1,654.83% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -952.31% |
NL
|
